Technical Analysis for BIIB - Biogen Idec Inc.

Grade Last Price % Change Price Change
grade C 235.91 0.00% 0.00
BIIB closed unchanged on Tuesday, June 25, 2019, on 1.16 times normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical BIIB trend table...

Date Alert Name Type % Chg
Shooting Star Candlestick Bearish 0.00%
Lizard Bearish Bearish Day Trade Setup 0.00%
Doji - Bearish? Reversal 0.00%
Upper Bollinger Band Walk Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Up 4 Days in a Row Strength 0.00%
Up 5 Days in a Row Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup 0.17%

Older signals for BIIB ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include AVONEX for the treatment of relapsing multiple sclerosis (MS); TYSABRI to treat relapsing MS; RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin's lymphoma (NHL); FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. The company's products that completed Phase III clinical trials comprise TECFIDERA (BG-12) for MS; Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a; and long-lasting Factor VIII and IX product candidates for the treatment of hemophilia. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; and ANTI-TWAEK for lupus nephritis. The company's Phase I clinical trial products comprise Anti-LINGO for MS; BIIB037 for Alzheimer's disease; Neublastin for neuropathic pain; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial product includes ISIS-SMNRx for spinal muscular atrophy. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.
Medicine Biotechnology Pain Immunology Monoclonal Antibodies Alzheimer's Disease Multiple Sclerosis Specialty Drugs Chronic Lymphocytic Leukemia Autoimmune Disorders Immunosuppressants Neurodegenerative Diseases Hemophilia Spinal Muscular Atrophy Idiopathic Pulmonary Fibrosis Treatment Of Hemophilia NHL Lupus Nephritis Clinical Trial Products
Is BIIB a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 388.67
52 Week Low 216.12
Average Volume 1,816,522
200-Day Moving Average 293.1075
50-Day Moving Average 229.3434
20-Day Moving Average 229.116
10-Day Moving Average 233.033
Average True Range 5.3489
ADX 21.82
+DI 29.7314
-DI 11.0904
Chandelier Exit (Long, 3 ATRs ) 229.3033
Chandelier Exit (Short, 3 ATRs ) 235.2467
Upper Bollinger Band 238.6233
Lower Bollinger Band 219.6087
Percent B (%b) 0.86
BandWidth 8.299115
MACD Line 1.3747
MACD Signal Line 0.1548
MACD Histogram 1.22
Fundamentals Value
Market Cap 49.88 Billion
Num Shares 211 Million
EPS 15.24
Price-to-Earnings (P/E) Ratio 15.48
Price-to-Sales 5.55
Price-to-Book 5.61
PEG Ratio 2.22
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 250.07
Resistance 3 (R3) 251.64 248.50 247.71
Resistance 2 (R2) 248.50 244.89 247.71 246.92
Resistance 1 (R1) 242.20 242.66 240.63 240.63 246.14
Pivot Point 239.06 239.06 238.27 238.27 239.06
Support 1 (S1) 232.76 235.45 231.19 231.19 225.68
Support 2 (S2) 229.62 233.22 228.83 224.90
Support 3 (S3) 223.32 229.62 224.11
Support 4 (S4) 221.75